| 2 | Chronic exposure to high-density polyethylene microplastic through feeding alters the nutrient metabolism of juvenile yellow perch (Perca flavescens)显示文摘Microplastics are emergent contaminants threatening aquatic organisms including aquacultured fish.This study investigated the effects of high-density polyethylene(HDPE,100 to 125 mm)on yellow perch(Perca flavescens)based on integrative evaluation including growth performance,nutritional status,nutrient metabolism,fish health,and gut microbial community.Five test diets(0,1,2,4,or 8 g HDPE/100 g diet)containing 41%protein and 10.5%lipid were fed to juvenile perch(average body weight,25.9±0.2 g;n=15)at a feeding rate of 1.5%to 2.0%body weight daily.The feeding trial was conducted in a flow-through water system for 9 wk with 3 tanks per treatment and 15 yellow perch per tank.No mortality or HDPE accumulation in the fish was found in any treatments.Weight gain and condition factor of fish were not significantly impacted by HDPE(P>0.05).Compared to the control group,fish fed the 8%HDPE diet had significantly decreased levels of protein and ash(P<0.05).In response to the increasing levels of HDPE exposure,the hepatosomatic index value,hepatocyte size,and liver glycogen level were increased,but lipid content was reduced in the liver tissues.Compared to the control treatment,fish fed the 8%HDPE diet had significant accumulations of total bile acids and different metabolism pathways such as bile acid biosynthesis,pyruvate metabolism,and carnitine synthesis.Significant enterocyte necrosis was documented in the foregut of fish fed the 2%or 8%HDPE diet;and significant cell sloughing was observed in the midgut and hindgut of fish fed the 8%HDPE diet.Fish fed the 2%HDPE diet harbored different microbiota communities compared to the control fish.This study demonstrates that HDPE ranging from 100 to 125 mm in feed can be evacuated by yellow perch with no impact on growth.However,dietary exposure to HDPE decreased whole fish nutrition quality,altered nutrient metabolism and the intestinal histopathology as well as microbiota community of yellow perch.The results indicate that extended exposure may pose a risk to fish health and jeopardize the nutrition quality of aquacultured end product.This hypothesis remains to be investigated further. | Xing Lu Dong-Fang Deng Fei Huang Fabio Casu Emma Kraco Ryan J.Newton Merry Zohn Swee J.Teh Aaron M.Watson Brian Shepherd Ying Ma Mahmound A.O.Dawood Lorena M.Rios Mendoza | 2022 | Animal Nutrition2022，，2： | 1 |
| 3 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员